Tyck till om SwePub Sök
här!
Sökning: WFRF:(Brenner Hermann)
> Karolinska Institutet >
Administration of a...
-
Babaei, MasoudGerman Canc Res Ctr, Div Clin Epidemiol & Aging Res, Heidelberg, Germany.;German Canc Res Ctr, Div Prevent Oncol, Heidelberg, Germany.;Natl Ctr Tumor Dis NCT, Heidelberg, Germany.
(författare)
Administration of adjuvant chemotherapy for stage II-III colon cancer patients : An European population-based study
- Artikel/kapitelEngelska2018
Förlag, utgivningsår, omfång ...
-
2017-12-04
-
WILEY,2018
-
printrdacarrier
Nummerbeteckningar
-
LIBRIS-ID:oai:DiVA.org:uu-346647
-
https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-346647URI
-
https://doi.org/10.1002/ijc.31168DOI
-
http://kipublications.ki.se/Default.aspx?queryparsed=id:137615486URI
Kompletterande språkuppgifter
-
Språk:engelska
-
Sammanfattning på:engelska
Ingår i deldatabas
Klassifikation
-
Ämneskategori:ref swepub-contenttype
-
Ämneskategori:art swepub-publicationtype
Anmärkningar
-
The advantage of adjuvant chemotherapy (ACT) for treating Stage III colon cancer patients is well established and widely accepted. However, many patients with Stage III colon cancer do not receive ACT. Moreover, there are controversies around the effectiveness of ACT for Stage II patients. We investigated the administration of ACT and its association with overall survival in resected Stage II (overall and stratified by low-/high-risk) and Stage III colon cancer patients in three European countries including The Netherlands (2009-2014), Belgium (2009-2013) and Sweden (2009-2014). Hazard ratios (HR) for death were obtained by Cox regression models adjusted for potential confounders. A total of 60244 resected colon cancer patients with pathological Stages II and III were analyzed. A small proportion (range 9-24%) of Stage II and over half (range 55-68%) of Stage III patients received ACT. Administration of ACT in Stages II and III tumors decreased with higher age of patients. Administration of ACT was significantly associated with higher overall survival in high-risk Stage II patients (in The Netherlands (HR; 95%CI = 0.82 (0.67-0.99), Belgium (0.73; 0.59-0.90) and Sweden (0.58; 0.44-0.75)), and in Stage III patients (in The Netherlands (0.47; 0.43-0.50), Belgium (0.46; 0.41-0.50) and Sweden (0.48; 0.43-0.54)). In Stage III, results were consistent across subgroups including elderly patients. Our results show an association of ACT with higher survival among Stage III and high-risk Stage II colon cancer patients. Further investigations are needed on the selection criteria of Stages II and III colon cancer patients for ACT.
Ämnesord och genrebeteckningar
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Balavarca, YesildaGerman Canc Res Ctr, Div Prevent Oncol, Heidelberg, Germany.;Natl Ctr Tumor Dis NCT, Heidelberg, Germany.
(författare)
-
Jansen, LinaGerman Canc Res Ctr, Div Clin Epidemiol & Aging Res, Heidelberg, Germany.
(författare)
-
Lemmens, ValeryNetherlands Comprehens Canc Org IKNL, Utrecht, Netherlands.;Erasmus MC Univ, Med Ctr, Dept Publ Hlth, Rotterdam, Netherlands.
(författare)
-
van Erning, Felice N.Netherlands Comprehens Canc Org IKNL, Utrecht, Netherlands.;Erasmus MC Univ, Med Ctr, Dept Publ Hlth, Rotterdam, Netherlands.
(författare)
-
van Eycken, LiesbetBelgian Canc Registry, Brussels, Belgium.
(författare)
-
Vaes, EvelienBelgian Canc Registry, Brussels, Belgium.
(författare)
-
Sjövall, AnnikaKarolinska Institutet
(författare)
-
Glimelius, BengtUppsala universitet,Experimentell och klinisk onkologi(Swepub:uu)bengglim
(författare)
-
Ulrich, Cornelia M.German Canc Res Ctr, Div Prevent Oncol, Heidelberg, Germany.;Natl Ctr Tumor Dis NCT, Heidelberg, Germany.;Huntsman Canc Inst, Salt Lake City, UT USA.;Univ Utah, Salt Lake City, UT USA.
(författare)
-
Schrotz-King, PetraGerman Canc Res Ctr, Div Prevent Oncol, Heidelberg, Germany.;Natl Ctr Tumor Dis NCT, Heidelberg, Germany.
(författare)
-
Brenner, HermannGerman Canc Res Ctr, Div Clin Epidemiol & Aging Res, Heidelberg, Germany.;German Canc Res Ctr, Div Prevent Oncol, Heidelberg, Germany.;Natl Ctr Tumor Dis NCT, Heidelberg, Germany.;German Canc Res Ctr, German Canc Consortium DKTK, Heidelberg, Germany.
(författare)
-
German Canc Res Ctr, Div Clin Epidemiol & Aging Res, Heidelberg, Germany.;German Canc Res Ctr, Div Prevent Oncol, Heidelberg, Germany.;Natl Ctr Tumor Dis NCT, Heidelberg, Germany.German Canc Res Ctr, Div Prevent Oncol, Heidelberg, Germany.;Natl Ctr Tumor Dis NCT, Heidelberg, Germany.
(creator_code:org_t)
Sammanhörande titlar
-
Ingår i:International Journal of Cancer: WILEY142:7, s. 1480-14890020-71361097-0215
Internetlänk
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Babaei, Masoud
-
Balavarca, Yesil ...
-
Jansen, Lina
-
Lemmens, Valery
-
van Erning, Feli ...
-
van Eycken, Lies ...
-
visa fler...
-
Vaes, Evelien
-
Sjövall, Annika
-
Glimelius, Bengt
-
Ulrich, Cornelia ...
-
Schrotz-King, Pe ...
-
Brenner, Hermann
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Cancer och onkol ...
- Artiklar i publikationen
-
International Jo ...
- Av lärosätet
-
Uppsala universitet
-
Karolinska Institutet